ProShares UltraShort Bloomberg Natrl Gas

MicroSectors Gold Miners 3X Leveraged ETN

ProShares Ultra Semiconductors

Mast Therapeutics, Inc.

Direxion Daily Gold Miners Bull 3X ETF

Direxion Dly S&P Oil&Gs Ex&Prd Br 3X ETF

Direxion Daily Semicondct Bear 3X ETF

VanEck Vectors Junior Gold Miners ETF

ProShares Short VIX Short-Term Futures

VS TR 2x Long VIX Futures ETF

ProShares Ultra Bloomberg Natural Gas

Volatility Shares Trust 2x Ether ETF

MicroSectors Gold Miners -3X Inverse Leveraged ETNs

United States Natural Gas

Direxion Daily TSLA Bull 1.5X Shares

GraniteShares 1.5x Short NVDA Daily ETF

ProShares Ultra DJ-AIG Crude Oi

Direxion Daily Gold Miners Bear 3X ETF

AXS 2X Innovation ETF

GraniteShares 1.25x Long Tesla Daily ETF

KWESST Micro Systems Inc. Common Stock

Protagenic Therapeutics Inc. Common Stock

DigiAsia Corp. Ordinary Shares

Healthcare Triangle Inc. Common Stock

Siyata Mobile Inc. Common Shares

Mullen Automotive Inc. Common Stock

NWTN Inc. Class B Ordinary Shares

Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares

ZK International Group Co. Ltd Ordinary Share

New Fortress Energy Inc. Class A Common Stock

Crown LNG Holdings Limited Ordinary Shares

MicroAlgo Inc. Ordinary Shares

QuantumScape Corporation Class A Common Stock

Incannex Healthcare Limited American Depositary Shares

Archer Aviation Inc. Class A Common Stock

Liquidia Corporation Common Stock

AgriFORCE  Growing Systems Ltd. Common Shares

First Solar Inc. Common Stock

Amesite Inc. Common Stock

AST SpaceMobile Inc. Class A Common Stock

Click here to get full coverage on BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - Stock Titan

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS  Stock Titan

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - Stock Titan

Click here to get full coverage on BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update  PR Newswire

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Click here to get full coverage on Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews

Pre-market Movers: HCTI, PTIX, BCLI, AFMD...  RTTNews

Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews

Click here to get full coverage on Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial - GuruFocus

Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial  GuruFocus

Brainstorm Cell Therapeutics (BCLI) Advances Phase 3b ALS Trial - GuruFocus

Click here to get full coverage on BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - Quantisnow

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS  Quantisnow

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - Quantisnow

Click here to get full coverage on BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting - PR Newswire

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting  PR Newswire

BrainStorm's NurOwn® Data Selected as Breakthrough Science for Presentation at ISCT 2025 Meeting - PR Newswire

Click here to get full coverage on Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary  TradingView

Brainstorm Cell Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary - TradingView

Click here to get full coverage on BrainStorm's NurOwn ALS Treatment Takes Major Step Forward: FDA Amendment Filed, Trial Sites Ready - Stock Titan

BrainStorm's NurOwn ALS Treatment Takes Major Step Forward: FDA Amendment Filed, Trial Sites Ready  Stock Titan

BrainStorm's NurOwn ALS Treatment Takes Major Step Forward: FDA Amendment Filed, Trial Sites Ready - Stock Titan

Click here to get full coverage on SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc. - Quantisnow

SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc.  Quantisnow

SEC Form 10-Q filed by Brainstorm Cell Therapeutics Inc. - Quantisnow

Click here to get full coverage on BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - PR Newswire

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS  PR Newswire

BrainStorm Cell Therapeutics Submits IND Amendment to FDA, Paving the Way for Phase 3b Trial of NurOwn® in ALS - PR Newswire

Click here to get full coverage on BrainStorm Cell Therapeutics Moves Q1 2025 Earnings Release to Today, Full Management Team to Host May 19 Call - Stock Titan

BrainStorm Cell Therapeutics Moves Q1 2025 Earnings Release to Today, Full Management Team to Host May 19 Call  Stock Titan

BrainStorm Cell Therapeutics Moves Q1 2025 Earnings Release to Today, Full Management Team to Host May 19 Call - Stock Titan

Click here to get full coverage on BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - Quantisnow

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19  Quantisnow

BrainStorm Reschedules First Quarter 2025 Financial Results Release to Post-Market Close Today and Sets Investor Call for Monday, May 19 - Quantisnow

Click here to get full coverage on BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - PR Newswire

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit  PR Newswire

BrainStorm to Present Biomarker Insights Supporting NurOwn's Mechanism of Action and Clinical Impact at the 2025 ALS Drug Development Summit - PR Newswire

Click here to get full coverage on BrainStorm Cell Slashes Losses by 33%, Secures FDA Agreement for Major ALS Trial - Stock Titan

BrainStorm Cell Slashes Losses by 33%, Secures FDA Agreement for Major ALS Trial  Stock Titan

BrainStorm Cell Slashes Losses by 33%, Secures FDA Agreement for Major ALS Trial - Stock Titan

Click here to get full coverage on BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update  PR Newswire

BrainStorm Cell Therapeutics Announces Full Year 2024 Financial Results and Provides Corporate Update - PR Newswire

Click here to get full coverage on BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update  PR Newswire

BrainStorm Cell Therapeutics Announces Third Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Click here to get full coverage on BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement  PR Newswire

BrainStorm Cell Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - PR Newswire

Click here to get full coverage on BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing  PR Newswire

BrainStorm Cell Therapeutics and Pluri Partner to Support NurOwn® Phase 3b Trial Manufacturing - PR Newswire

Click here to get full coverage on BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - PR Newswire

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq  PR Newswire

BrainStorm Cell Therapeutics Granted Compliance Extension from Nasdaq - PR Newswire

Click here to get full coverage on BCLI - Brainstorm Cell Therapeutics I Latest Stock News & Market Updates - Stock Titan

BCLI - Brainstorm Cell Therapeutics I Latest Stock News & Market Updates  Stock Titan

BCLI - Brainstorm Cell Therapeutics I Latest Stock News & Market Updates - Stock Titan

Click here to get full coverage on BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update  PR Newswire

BrainStorm Cell Therapeutics Announces Second Quarter 2024 Financial Results and Provides Corporate Update - PR Newswire

Click here to get full coverage on BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - PR Newswire

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology  PR Newswire

BrainStorm Strengthens Exosome Patent Portfolio: Receives Notice of Allowance for U.S. Patent Covering Its Platform Technology - PR Newswire

Click here to get full coverage on BrainStorm Cell Therapeutics Sets Major Investor Briefing: CEO, COO, and CMO to Reveal 2024 Performance - Stock Titan

BrainStorm Cell Therapeutics Sets Major Investor Briefing: CEO, COO, and CMO to Reveal 2024 Performance  Stock Titan

BrainStorm Cell Therapeutics Sets Major Investor Briefing: CEO, COO, and CMO to Reveal 2024 Performance - Stock Titan

Click here to get full coverage on Groundbreaking ALS Treatment Discovery: How Genetics May Predict NurOwn Therapy Success - Stock Titan

Groundbreaking ALS Treatment Discovery: How Genetics May Predict NurOwn Therapy Success  Stock Titan

Groundbreaking ALS Treatment Discovery: How Genetics May Predict NurOwn Therapy Success - Stock Titan

Click here to get full coverage on BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update - PR Newswire

BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update  PR Newswire

BrainStorm to Announce Fourth Quarter and Fiscal Year 2024 Financial Results and Provide a Corporate Update - PR Newswire

Click here to get full coverage on BrainStorm's ALS Treatment Breakthrough: New Biomarker Data Shows Promise as FDA-Approved Trial Approaches - Stock Titan

BrainStorm's ALS Treatment Breakthrough: New Biomarker Data Shows Promise as FDA-Approved Trial Approaches  Stock Titan

BrainStorm's ALS Treatment Breakthrough: New Biomarker Data Shows Promise as FDA-Approved Trial Approaches - Stock Titan

Click here to get full coverage on SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit  ACCESS Newswire

SHAREHOLDER ALERT: Potential Recovery for Brainstorm Cell Therapeutics Inc. (BCLI) Investors Affected by Stock Drop - Levi & Korsinsky Pursuing Class Action Lawsuit - ACCESS Newswire

Click here to get full coverage on BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial - PR Newswire

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial  PR Newswire

BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial - PR Newswire

Click here to get full coverage on BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering - PR Newswire

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering  PR Newswire

BrainStorm Cell Therapeutics Announces Pricing of $4.0 Million Registered Direct Offering - PR Newswire

Click here to get full coverage on Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - Investing.com

Brainstorm Cell Therapeutics Appeals Nasdaq Delisting  Investing.com

Brainstorm Cell Therapeutics Appeals Nasdaq Delisting - Investing.com

Click here to get full coverage on Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting - Investing.com

Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting  Investing.com

Earnings call transcript: Brainstorm Cell Therapeutics Q4 2024 highlights cost-cutting - Investing.com

Click here to get full coverage on BrainStorm receives Nasdaq listing extension to June 30 - Investing.com

BrainStorm receives Nasdaq listing extension to June 30  Investing.com

BrainStorm receives Nasdaq listing extension to June 30 - Investing.com

Click here to get full coverage on Brainstorm Cell Therapeutics faces Nasdaq delisting - Investing.com

Brainstorm Cell Therapeutics faces Nasdaq delisting  Investing.com

Brainstorm Cell Therapeutics faces Nasdaq delisting - Investing.com

Click here to get full coverage on 12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session  Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Click here to get full coverage on symbol__ Stock Quote Price and Forecast - CNN

symbol__ Stock Quote Price and Forecast  CNN

symbol__ Stock Quote Price and Forecast - CNN

Click here to get full coverage on 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session  Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Click here to get full coverage on BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update - PR Newswire

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update  PR Newswire

BrainStorm Cell Therapeutics Announces Full Year 2023 Financial Results and Provides Corporate Update - PR Newswire

Click here to get full coverage on BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™… - Yahoo Finance

BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™…  Yahoo Finance

BCLI: Receives SPA Agreement from FDA on Design of Phase 3b Trial of NurOwn™… - Yahoo Finance

Click here to get full coverage on Elder law centre moves to Faculty of Law - Campus Life - Kamloops - Castanet

Elder law centre moves to Faculty of Law - Campus Life - Kamloops  Castanet

Elder law centre moves to Faculty of Law - Campus Life - Kamloops - Castanet

Click here to get full coverage on BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS… - Yahoo Finance

BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS…  Yahoo Finance

BCLI: Unveils Plans for Phase 3b Trial of NurOwn® in ALS… - Yahoo Finance

Click here to get full coverage on EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. – BCLI - Business Wire

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. – BCLI  Business Wire

EQUITY ALERT: Rosen Law Firm Files Securities Class Action Lawsuit Against Brainstorm Cell Therapeutics Inc. – BCLI - Business Wire

Click here to get full coverage on ROSEN, A RANKED AND LEADING FIRM, Encourages Brainstorm - GlobeNewswire

ROSEN, A RANKED AND LEADING FIRM, Encourages Brainstorm  GlobeNewswire

ROSEN, A RANKED AND LEADING FIRM, Encourages Brainstorm - GlobeNewswire

Click here to get full coverage on BCLI Stock Price and Chart — NASDAQ:BCLI - TradingView

BCLI Stock Price and Chart — NASDAQ:BCLI  TradingView

BCLI Stock Price and Chart — NASDAQ:BCLI - TradingView

Click here to get full coverage on Canadian Centre for Elder Law moves to Thompson Rivers University law school - Canadian Lawyer Magazine

Canadian Centre for Elder Law moves to Thompson Rivers University law school  Canadian Lawyer Magazine

Canadian Centre for Elder Law moves to Thompson Rivers University law school - Canadian Lawyer Magazine

Click here to get full coverage on Metro Vancouver Active Control Points Map - BC Gov

Metro Vancouver Active Control Points Map  BC Gov

Metro Vancouver Active Control Points Map - BC Gov

Click here to get full coverage on Indo-Asian News Service - Indo-Asian News Service (IANS)

Indo-Asian News Service  Indo-Asian News Service (IANS)

Indo-Asian News Service - Indo-Asian News Service (IANS)

Click here to get full coverage on Brainstorm Cell Therapeutics (BCLI) - Zacks Investment Research

Brainstorm Cell Therapeutics (BCLI)  Zacks Investment Research

Brainstorm Cell Therapeutics (BCLI) - Zacks Investment Research

Click here to get full coverage on Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis - MarketBeat

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis  MarketBeat

Brainstorm Cell Therapeutics (BCLI) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Brainstorm Cell Therapeutics Misses Q3 EPS by 35c - Investing.com Canada

Brainstorm Cell Therapeutics Misses Q3 EPS by 35c  Investing.com Canada

Brainstorm Cell Therapeutics Misses Q3 EPS by 35c - Investing.com Canada

Click here to get full coverage on Figure 2: Maps of new plasmids for CRISPR–Cas9 genome editing in... - ResearchGate

Figure 2: Maps of new plasmids for CRISPR–Cas9 genome editing in...  ResearchGate

Figure 2: Maps of new plasmids for CRISPR–Cas9 genome editing in... - ResearchGate

Click here to get full coverage on Emily Clough appointed to BC Law Institute’s Board of Directors - Clark Wilson LLP

Emily Clough appointed to BC Law Institute’s Board of Directors  Clark Wilson LLP

Emily Clough appointed to BC Law Institute’s Board of Directors - Clark Wilson LLP

Click here to get full coverage on BrainStorm tanks after Phase III failure - גלובס

BrainStorm tanks after Phase III failure  גלובס

BrainStorm tanks after Phase III failure - גלובס

Click here to get full coverage on StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World

StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI)  Defense World

StockNews.com Begins Coverage on Brainstorm Cell Therapeutics (NASDAQ:BCLI) - Defense World

Click here to get full coverage on Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Thursday - Defense World

Brainstorm Cell Therapeutics (BCLI) to Release Earnings on Thursday  Defense World

Brainstorm Cell Therapeutics Inc (BCLI)

Price Chart

Key Statistics

Technicals

About BCLI

Latest News

BrainStorm Receives FDA Clearance to Initiate Phase 3b Trial of NurOwn® for ALS - Stock Titan

BrainStorm Cell Therapeutics Announces First Quarter 2025 Financial Results and Provides Corporate Update - PR Newswire

Pre-market Movers: HCTI, PTIX, BCLI, AFMD... - RTTNews

Advanced Charts

Top Gainers

Top Losers